"According to President and Chief Executive Officer Daniel M. Bradbury and his management team, exenatide once weekly is on track for a planned launch in 2010"
The absolute last person anyone should be quoting is Dan Bradbury. I agree with the above poster. Amylin is the worst run company probably on the Nasdaq. The board and management both need to go, particularly the greedy, incompetent, arrogant, and pathetic Chairman of the Board. Regardless of the potential of the product, if you don't have a capable captain and crew steering the ship you will go no place fast. That has been clear the past two years.
-
"According to President and Chief Executive Officer Daniel M. Bradbury and his management team, exenatide once weekly is on track for a planned launch in 2010"
Apr 10 09:22 am
|Rating:
+2
-1
All Comments by Furd Turgeson »Amylin's Pullback Is Unjustified [View article]
The absolute last person anyone should be quoting is Dan Bradbury. I agree with the above poster. Amylin is the worst run company probably on the Nasdaq. The board and management both need to go, particularly the greedy, incompetent, arrogant, and pathetic Chairman of the Board. Regardless of the potential of the product, if you don't have a capable captain and crew steering the ship you will go no place fast. That has been clear the past two years.